nach oben

International Journal of Colorectal Disease

Erschienen in:

01.06.2009 | Original Article

Estrogen receptor α/β, AIB1, and TIF2 in colorectal carcinogenesis: do coregulators have prognostic significance?

verfasst von: Petros D. Grivas, Vassiliki Tzelepi, Georgia Sotiropoulou-Bonikou, Zinovia Kefalopoulou, Athanasios G. Papavassiliou, Haralabos Kalofonos

Erschienen in: International Journal of Colorectal Disease | Ausgabe 6/2009

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Estrogen receptor β (ERβ) is abundantly expressed in colorectal tissue, but its role in colorectal carcinogenesis remains elusive. Estrogen receptor coregulators, amplified in breast cancer 1 (AIB1) and transcription intermediary factor 2 (TIF2), have been well-characterized, but their expression in colorectal carcinomas has not been investigated.

Materials and methods

Estrogen receptor α (ERα), ERβ, AIB1, and TIF2 protein expression were evaluated by immunohistochemistry in colorectal normal mucosa, adenomas, and adenocarcinomas from 110 patients with colorectal cancer.

Results

ERα expression was rare in colorectal tissue and its expression does not appear to be associated with colorectal carcinogenesis. ERβ, AIB1, and TIF2 were detected in the nucleus of epithelial, endothelial, inflammatory, smooth muscle cells, and myofibroblasts. The expression of the three proteins was significantly increased in epithelial cells of carcinomas compared to normal mucosa. In carcinomas, a significant correlation between the levels of expression of AIB1 and TIF2 was noted. Although AIB1 overexpression was associated with local tumor invasion, it was also found to correlate independently with prolonged overall survival.

Conclusions

ERβ, AIB1, and TIF2 appear to be involved in colorectal tumorigenesis and might have prognostic significance.

Fiorelli G, Picariello L, Martineti V, Tonelli F, Brandi ML (1999) Functional estrogen receptor beta in colon cancer cells. Biochem Biophys Res Commun 261:521–527PubMedCrossRef

Konstantinopoulos PA, Kominea A, Vandoros G et al (2003) Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour’s dedifferentiation. Eur J Cancer 39:1251–1258PubMedCrossRef

Moore JT, McKee DD, Slentz-Kesler K et al (1998) Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun 247:75–78PubMedCrossRef

Cavallini A, Messa C, Pricci M, Caruso ML, Barone M, Di Leo A (2002) Distribution of estrogen receptor subtypes, expression of their variant forms, and clinicopathological characteristics of human colorectal cancer. Dig Dis Sci 47:2720–2728PubMedCrossRef

Nilsson S, Makela S, Treuter E et al (2001) Mechanisms of estrogen action. Physiol Rev 81:1535–1565PubMed

Jensen EV, Jordan VC (2003) The estrogen receptor: a model for molecular medicine. Clin Cancer Res 9:1980–1989PubMed

Peng B, Lu B, Leygue E, Murphy LC (2003) Putative functional characteristics of human estrogen receptor-beta isoforms. J Mol Endocrinol 30:13–29PubMedCrossRef

Acconcia F, Kumar R (2006) Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett 238:1–14PubMedCrossRef

Lonard DM, O’Malley BW (2007) Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. Mol Cell 27:691–700PubMedCrossRef

10.

Anzick SL, Kononen J, Walker RL et al (1997) AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277:965–968PubMedCrossRef

11.

Glaeser MT, Hanstein B, Beckmann MW, Niederacher D (2001) Gene amplification and expression of the steroid receptor coactivator SRC3 (AIB1) in sporadic breast and endometrial carcinomas. Horm Metab Res 33:121–126PubMedCrossRef

12.

Sakakura C, Hagiwara A, Yasuoka R et al (2000) Amplification and over-expression of the AIB1 nuclear receptor co-activator gene in primary gastric cancers. Int J Cancer 89:217–223PubMedCrossRef

13.

Wang Y, Wu MC, Sham JS, Zhang W, Wu WQ, Guan XY (2002) Prognostic significance of c-myc and AIB1 amplification in hepatocellular carcinoma. A broad survey using high-throughput tissue microarray. Cancer 95:2346–2352PubMedCrossRef

14.

Gnanapragasam VJ, Leung HY, Pulimood AS, Neal DE, Robson CN (2001) Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. Br J Cancer 85:1928–1936PubMedCrossRef

15.

Torres-Arzayus MI, Font de Mora J, Yuan J et al (2004) High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 6:263–274PubMedCrossRef

16.

Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415–428PubMedCrossRef

17.

Lund AH, van Lohuizen M (2004) Epigenetics and cancer. Genes Dev 18:2315–2335PubMedCrossRef

18.

Louie MC, Revenko AS, Zou JX, Yao J, Chen HW (2006) Direct control of cell cycle gene expression by proto-oncogene product ACTR, and its autoregulation underlies its transforming activity. Mol Cell Biol 26:3810–3823PubMedCrossRef

19.

Louie MC, Zou JX, Rabinovich A, Chen HW (2004) ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance. Mol Cell Biol 24:5157–5171PubMedCrossRef

20.

Voegel JJ, Heine MJ, Zechel C, Chambon P, Gronemeyer H (1996) TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J 15:3667–3675PubMed

21.

Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK, Rosenfeld MG (1997) The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 387:677–684PubMedCrossRef

22.

Giannini R, Cavallini A (2005) Expression analysis of a subset of coregulators and three nuclear receptors in human colorectal carcinoma. Anticancer Res 25:4287–4292PubMed

23.

Mukherjee A, Amato P, Allred DC et al (2006) Steroid receptor coactivator 2 is essential for progesterone-dependent uterine function and mammary morphogenesis: insights from the mouse—implications for the human. J Steroid Biochem Mol Biol 102:22–31PubMedCrossRef

24.

Picard F, Gehin M, Annicotte J et al (2002) SRC-1 and TIF2 control energy balance between white and brown adipose tissues. Cell 111:931–941PubMedCrossRef

25.

Dunlop TW, Vaisanen S, Frank C, Carlberg C (2004) The genes of the coactivator TIF2 and the corepressor SMRT are primary 1alpha,25(OH)2D3 targets. J Steroid Biochem Mol Biol 89–90:257–260PubMedCrossRef

26.

Holt PR, Arber N, Halmos B et al (2002) Colonic epithelial cell proliferation decreases with increasing levels of serum 25-hydroxy vitamin D. Cancer Epidemiol Biomarkers Prev 11:113–119PubMed

27.

Duong BN, Elliott S, Frigo DE et al (2006) AKT regulation of estrogen receptor beta transcriptional activity in breast cancer. Cancer Res 66:8373–8381PubMedCrossRef

28.

Jassam N, Bell SM, Speirs V, Quirke P (2005) Loss of expression of oestrogen receptor beta in colon cancer and its association with Dukes’ staging. Oncol Rep 14:17–21PubMed

29.

Witte D, Chirala M, Younes A, Li Y, Younes M (2001) Estrogen receptor beta is expressed in human colorectal adenocarcinoma. Hum Pathol 32:940–944PubMedCrossRef

30.

Wong NA, Malcomson RD, Jodrell DI, Groome NP, Harrison DJ, Saunders PT (2005) ERbeta isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates. J Pathol 207:53–60PubMedCrossRef

31.

Secreto FJ, Monroe DG, Dutta S, Ingle JN, Spelsberg TC (2007) Estrogen receptor alpha/beta isoforms, but not betacx, modulate unique patterns of gene expression and cell proliferation in Hs578T cells. J Cell Biochem 101(5):1125–1147PubMedCrossRef

32.

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol 2:416–422PubMedCrossRef

33.

Singh S, Poulsom R, Hanby AM, Rogers LA, Wright NA, Sheppard MC, Langman MJ (1998) Expression of oestrogen receptor and oestrogen-inducible genes pS2 and ERD5 in large bowel mucosa and cancer. J Pathol 184(2):153–160PubMedCrossRef

34.

Cho NL, Redston N, Zauber AG et al (2008) Aberrant crypt foci in the adenoma prevention with celecoxib trial. Cancer Prev Res 1:21–31 doi:10.1158/1940-6207.CAPR-07-0011 CrossRef

35.

Foley EF, Jazaeri AA, Shupnik MA, Jazaeri O, Rice LW (2000) Selective loss of estrogen receptor beta in malignant human colon. Cancer Res 60:245–248PubMed

36.

Campbell-Thompson M, Lynch IJ, Bhardwaj B (2001) Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer Res 61:632–640PubMed

37.

Cho NL, Javid SH, Carothers AM, Redston M, Bertagnolli MM (2007) Estrogen receptors alpha and beta are inhibitory modifiers of Apc-dependent tumorigenesis in the proximal colon of Min/ + mice. Cancer Res 67(5):2366–2372PubMedCrossRef

38.

Giroux V, Lemay F, Bernatchez G, Robitaille Y, Carrier JC (2008) Estrogen receptor beta deficiency enhances small intestinal tumorigenesis in ApcMin/+ mice. Int J Cancer 123(2):303–311PubMedCrossRef

39.

O’Neill PA, Davies MP, Shaaban AM, Innes H, Torevell A, Sibson DR, Foster CS (2004) Wild-type oestrogen receptor beta (ERbeta1) mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancers. Br J Cancer 91(9):1694–1702PubMed

40.

Balfe PJ, McCann AH, Welch HM, Kerin MJ (2004) Estrogen receptor beta and breast cancer. Eur J Surg Oncol 30(10):1043–1050PubMedCrossRef

41.

Gunter MJ, Hoover DR, Yu H et al (2008) Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. Cancer Res 68:329–337PubMedCrossRef

42.

Narayan S, Rajakumar G, Prouix H, Singh P (1992) Estradiol is trophic for colon cancer in mice: effect on ornithine decarboxylase and c-myc messenger RNA. Gastroenterology 103:1823–1832PubMed

43.

Singh S, Paraskeva C, Gallimore PH, Sheppard MC, Langman MJ (1994) Differential growth response to oestrogen of premalignant and malignant colonic cell lines. Anticancer Res 14:1037–1041PubMed

44.

Winter DC, Taylor C, C O’Sullivan G, Harvey BJ (2000) Mitogenic effects of oestrogen mediated by a non-genomic receptor in human colon. Br J Surg 87:1684–1689PubMedCrossRef

45.

Arai N, Strom A, Rafter JJ, Gustafsson JA (2000) Estrogen receptor beta mRNA in colon cancer cells: growth effects of estrogen and genistein. Biochem Biophys Res Commun 270:425–431PubMedCrossRef

46.

Di Domenico M, Castoria G, Bilancio A, Migliaccio A, Auricchio F (1996) Estradiol activation of human colon carcinoma-derived Caco-2 cell growth. Cancer Res 56:4516–4521PubMed

47.

Hennessy BA, Harvey BJ, Healy V (2005) 17beta-Estradiol rapidly stimulates c-fos expression via the MAPK pathway in T84 cells. Mol Cell Endocrinol 229:39–47PubMedCrossRef

48.

Wade CB, Robinson S, Shapiro RA, Dorsa DM (2001) Estrogen receptor (ER)alpha and ERbeta exhibit unique pharmacologic properties when coupled to activation of the mitogen-activated protein kinase pathway. Endocrinology 142:2336–2342PubMedCrossRef

49.

Oduwole OO, Isomaa VV, Nokelainen PA, Stenback F, Vihko PT (2002) Downregulation of estrogen-metabolizing 17 beta-hydroxysteroid dehydrogenase type 2 expression correlates inversely with Ki67 proliferation marker in colon-cancer development. Int J Cancer 97:1–6PubMedCrossRef

50.

English MA, Kane KF, Cruickshank N, Langman MJ, Stewart PM, Hewison M (1999) Loss of estrogen inactivation in colonic cancer. J Clin Endocrinol Metab 84:2080–2085PubMedCrossRef

51.

Guo JY, Li X, Browning JD et al (2004) Dietary soy isoflavones and estrone protect ovariectomized ERalphaKO and wild-type mice from carcinogen-induced colon cancer. J Nutr 134:179–182PubMed

52.

Hudelist G, Czerwenka K, Kubista E, Marton E, Pischinger K, Singer CF (2003) Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator. Breast Cancer Res Treat 78:193–204PubMedCrossRef

53.

Balmer NN, Richer JK, Spoelstra NS, Torkko KC, Lyle PL, Singh M (2006) Steroid receptor coactivator AIB1 in endometrial carcinoma, hyperplasia and normal endometrium: correlation with clinicopathologic parameters and biomarkers. Mod Pathol 19:1593–1605PubMedCrossRef

54.

Xie D, Sham JS, Zeng WF et al (2005) Correlation of AIB1 overexpression with advanced clinical stage of human colorectal carcinoma. Hum Pathol 36:777–783PubMedCrossRef

55.

Henke RT, Haddad BR, Kim SE et al (2004) Overexpression of the nuclear receptor coactivator AIB1 (SRC-3) during progression of pancreatic adenocarcinoma. Clin Cancer Res 10:6134–6142PubMedCrossRef

56.

Avivar A, Garcia-Macias MC, Ascaso E, Herrera G, O’Connor JE, de Mora JF (2006) Moderate overexpression of AIB1 triggers pre-neoplastic changes in mammary epithelium. FEBS Lett 580:5222–5226PubMedCrossRef

57.

Zhou G, Hashimoto Y, Kwak I, Tsai SY Tsai MJ (2003) Role of the steroid receptor coactivator SRC-3 in cell growth. Mol Cell Biol 23:7742–7755PubMedCrossRef

58.

List HJ, Lauritsen KJ, Reiter R, Powers C, Wellstein A, Riegel AT (2001) Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells. J Biol Chem 276:23763–23768PubMedCrossRef

59.

Zhou HJ, Yan J, Luo W et al (2005) SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res 65:7976–7983PubMed

60.

Kuang SQ, Liao L, Wang S, Medina D, O’Malley BW, Xu J (2005) Mice lacking the amplified in breast cancer 1/steroid receptor coactivator-3 are resistant to chemical carcinogen-induced mammary tumorigenesis. Cancer Res 65:7993–8002PubMed

61.

Xu FP, Xie D, Wen JM et al (2007) SRC-3/AIB1 protein and gene amplification levels in human esophageal squamous cell carcinomas. Cancer Lett 245:69–74PubMedCrossRef

62.

Zhang H, Stephens LC, Kumar R (2006) Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer. Clin Cancer Res 12:1479–1486PubMedCrossRef

63.

Li LB, Louie MC, Chen HW, Zou JX (2008) Proto-oncogene ACTR/AIB1 promotes cancer cell invasion by up-regulating specific matrix metalloproteinase expression. Cancer Lett 261:64–73PubMedCrossRef

64.

Kirkegaard T, McGlynn LM, Campbell FM et al (2007) Amplified in breast cancer 1 in human epidermal growth factor receptor-positive tumors of tamoxifen-treated breast cancer patients. Clin Cancer Res 13:1405–1411PubMedCrossRef

65.

Luo JH, Xie D, Liu MZ et al (2008) Protein expression and amplification of AIB1 in human urothelial carcinoma of the bladder and overexpression of AIB1 is a new independent prognostic marker of patient survival. Int J Cancer 122:2554–2561PubMedCrossRef

66.

Coste A, Antal MC, Chan S, Kastner P, Mark M, O’Malley BW, Auwerx J (2006) Absence of the steroid receptor coactivator-3 induces B-cell lymphoma. EMBO J 25:2453–2464PubMedCrossRef

67.

Chen SL, Wang SC, Hosking B, Muscat GE (2001) Subcellular localization of the steroid receptor coactivators (SRCs) and MEF2 in muscle and rhabdomyosarcoma cells. Mol Endocrinol 15:783–796PubMedCrossRef

68.

Kurebayashi J, Otsuki T, Kunisue H, Tanaka K, Yamamoto S, Sonoo H (2000) Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer. Clin Cancer Res 6:512–518PubMed

69.

Yan J, Tsai SY, Tsai MJ (2006) SRC-3/AIB1: transcriptional coactivator in oncogenesis. Acta Pharmacol Sin 27:387–394PubMedCrossRef

70.

Yan J, Yu CT, Ozen M, Ittmann M, Tsai SY, Tsai MJ (2006) Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway. Cancer Res 66:11039–11046PubMedCrossRef

Titel: Estrogen receptor α/β, AIB1, and TIF2 in colorectal carcinogenesis: do coregulators have prognostic significance?
verfasst von: Petros D. Grivas
Vassiliki Tzelepi
Georgia Sotiropoulou-Bonikou
Zinovia Kefalopoulou
Athanasios G. Papavassiliou
Haralabos Kalofonos
Publikationsdatum: 01.06.2009
Verlag: Springer-Verlag
Erschienen in: International Journal of Colorectal Disease / Ausgabe 6/2009
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-009-0647-9

Neu im Fachgebiet Chirurgie

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Estrogen receptor α/β, AIB1, and TIF2 in colorectal carcinogenesis: do coregulators have prognostic significance?